Michael H. Serrano‐Wu

2.3k total citations · 1 hit paper
31 papers, 1.4k citations indexed

About

Michael H. Serrano‐Wu is a scholar working on Molecular Biology, Organic Chemistry and Hepatology. According to data from OpenAlex, Michael H. Serrano‐Wu has authored 31 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 8 papers in Organic Chemistry and 6 papers in Hepatology. Recurrent topics in Michael H. Serrano‐Wu's work include Hepatitis C virus research (6 papers), Synthesis and Characterization of Heterocyclic Compounds (3 papers) and Cancer therapeutics and mechanisms (3 papers). Michael H. Serrano‐Wu is often cited by papers focused on Hepatitis C virus research (6 papers), Synthesis and Characterization of Heterocyclic Compounds (3 papers) and Cancer therapeutics and mechanisms (3 papers). Michael H. Serrano‐Wu collaborates with scholars based in United States, Canada and China. Michael H. Serrano‐Wu's co-authors include Lawrence B. Snyder, Nicholas A. Meanwell, Julie A. Lemm, Donald R. O’Boyle, Min Gao, Richard J. Colonno, Jin-Hua Sun, Van N. Nguyen, Makonen Belema and Robert A. Fridell and has published in prestigious journals such as Nature, PLoS ONE and Cancer Research.

In The Last Decade

Michael H. Serrano‐Wu

29 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

2010 689 citations Min Gao, Richard E. Nettles et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael H. Serrano‐Wu United States	18	795	633	350	342	307	31	1.4k
Robert B. Perni United States	23	868 1.1×	988 1.6×	424 1.2×	609 1.8×	506 1.6×	49	2.4k
Makonen Belema United States	13	749 0.9×	558 0.9×	322 0.9×	280 0.8×	292 1.0×	18	1.2k
Wonsuk Chang United States	17	567 0.7×	458 0.7×	671 1.9×	571 1.7×	435 1.4×	28	1.6k
Pierre Raboisson Belgium	24	636 0.8×	534 0.8×	497 1.4×	634 1.9×	555 1.8×	60	1.8k
Tsuyoshi Adachi Japan	12	694 0.9×	406 0.6×	305 0.9×	370 1.1×	177 0.6×	20	1.2k
Shalini Bansal United States	14	710 0.9×	609 1.0×	654 1.9×	440 1.3×	224 0.7×	29	1.4k
Bruce S. Ross United States	17	551 0.7×	452 0.7×	644 1.8×	762 2.2×	351 1.1×	42	1.6k
Christine Espiritu United States	17	1.1k 1.4×	1.0k 1.6×	810 2.3×	502 1.5×	163 0.5×	34	1.8k
Michel Garneau Canada	21	286 0.4×	339 0.5×	289 0.8×	495 1.4×	212 0.7×	57	1.3k
Van N. Nguyen United States	12	639 0.8×	498 0.8×	260 0.7×	219 0.6×	303 1.0×	14	1.1k

Countries citing papers authored by Michael H. Serrano‐Wu

Since Specialization

Citations

This map shows the geographic impact of Michael H. Serrano‐Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael H. Serrano‐Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael H. Serrano‐Wu more than expected).

Fields of papers citing papers by Michael H. Serrano‐Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael H. Serrano‐Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael H. Serrano‐Wu. The network helps show where Michael H. Serrano‐Wu may publish in the future.

Co-authorship network of co-authors of Michael H. Serrano‐Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Michael H. Serrano‐Wu. A scholar is included among the top collaborators of Michael H. Serrano‐Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael H. Serrano‐Wu. Michael H. Serrano‐Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Poulsen, Bradley E., Thulasi Warrier, Josephine Bagnall, et al.. (2024). Discovery of a Pseudomonas aeruginosa-specific small molecule targeting outer membrane protein OprH-LPS interaction by a multiplexed screen. Cell chemical biology. 32(2). 307–324.e15. 2 indexed citations

Serrano‐Wu, Michael H., Georgios Kosmidis, Stefan Kaulfuß, et al.. (2023). Abstract 506: ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models. Cancer Research. 83(7_Supplement). 506–506. 1 indexed citations

MacNair, Craig R., Maya A. Farha, Michael H. Serrano‐Wu, et al.. (2022). Preclinical Development of Pentamidine Analogs Identifies a Potent and Nontoxic Antibiotic Adjuvant. ACS Infectious Diseases. 8(4). 768–777. 22 indexed citations

Özcan, Lale, Canan Kasikara, Arif Yurdagul, et al.. (2021). Allosteric MAPKAPK2 inhibitors improve plaque stability in advanced atherosclerosis. PLoS ONE. 16(5). e0246600–e0246600. 4 indexed citations

Côté, Jean‐Philippe, Shawn French, Michael H. Serrano‐Wu, et al.. (2021). Chemical Screen for Vancomycin Antagonism Uncovers Probes of the Gram-Negative Outer Membrane. ACS Chemical Biology. 16(5). 929–942. 36 indexed citations

Nietupski, Raymond, Robert H. Bates, Eva María López-Román, et al.. (2018). Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(22). 3529–3533. 15 indexed citations

Nakajima, Katsumasa, J.T. Brewer, Thomas Daniels, et al.. (2016). Discovery of diamide compounds as diacylglycerol acyltransferase 1 (DGAT1) inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(4). 1245–1248. 5 indexed citations

Özcan, Lale, Xiaoming Xu, Shi‐Xian Deng, et al.. (2015). Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity. Diabetes. 64(10). 3396–3405. 23 indexed citations

Reilly, John, Sarah Williams, Cornelia J. Forster, et al.. (2015). High-Throughput Melanin-Binding Affinity and In Silico Methods to Aid in the Prediction of Drug Exposure in Ocular Tissue. Journal of Pharmaceutical Sciences. 104(12). 3997–4001. 18 indexed citations

10.

O’Boyle, Donald R., Jin-Hua Sun, Peter T. Nower, et al.. (2013). Characterizations of HCV NS5A replication complex inhibitors. Virology. 444(1-2). 343–354. 35 indexed citations

11.

Kawanami, Toshio, et al.. (2013). Efficient preparation of Ellman’s imines from trifluoromethyl ketones promoted by zirconium(IV) tert-butoxide. Tetrahedron Letters. 54(52). 7202–7205. 8 indexed citations

12.

Lopez, Omar D., Van N. Nguyen, Denis R. St. Laurent, et al.. (2012). HCV NS5A replication complex inhibitors. Part 3 : discovery of potent analogs with distinct core topologies. Bioorganic & Medicinal Chemistry Letters. 23(3). 779–784. 23 indexed citations

13.

Kwak, Young‐Shin, Gary M. Coppola, Cornelia J. Forster, et al.. (2011). A new structural alert for benzimidazoles: 2,6-Dimethylphenyl substituents increase mutagenic potential and time-dependent CYP3A4 inhibition risk. Bioorganic & Medicinal Chemistry Letters. 21(5). 1422–1424.

14.

Lemm, Julie A., John E. Leet, Donald R. O’Boyle, et al.. (2011). Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures. Antimicrobial Agents and Chemotherapy. 55(8). 3795–3802. 38 indexed citations

15.

Gao, Min, Richard E. Nettles, Makonen Belema, et al.. (2010). Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 465(7294). 96–100. 689 indexed citations breakdown →

16.

Lemm, Julie A., Donald R. O’Boyle, Mengping Liu, et al.. (2009). Identification of Hepatitis C Virus NS5A Inhibitors. Journal of Virology. 84(1). 482–491. 149 indexed citations

17.

Laurent, Denis R. St., Qi Gao, Dedong Wu, & Michael H. Serrano‐Wu. (2004). Regioselective synthesis of 3-(heteroaryl)-iminothiazolidin-4-ones. Tetrahedron Letters. 45(9). 1907–1910. 45 indexed citations

18.

Serrano‐Wu, Michael H., Denis R. St. Laurent, Marco Dodier, et al.. (2003). Identification of a broad-Spectrum azasordarin with improved pharmacokinetic properties. Bioorganic & Medicinal Chemistry Letters. 13(8). 1419–1423. 11 indexed citations

19.

Serrano‐Wu, Michael H., Denis R. St. Laurent, Yijun Chen, et al.. (2002). Sordarin Oxazepine Derivatives as Potent Antifungal Agents. Bioorganic & Medicinal Chemistry Letters. 12(19). 2757–2760. 49 indexed citations

20.

Serrano‐Wu, Michael H., et al.. (2001). Mild deprotection of 2-(trimethylsilyl)ethyl esters. Tetrahedron Letters. 42(49). 8593–8595. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact